| Table 5. Comparison of ovarian stimulation data and outcomes between patients undergoing stimulation with rFSH or hp-hMG among women treated with the GnRH antagonist protocol* | ||||||||
| rFSH (n=296) |
hp-hMG (n=87) |
p value | ||||||
|---|---|---|---|---|---|---|---|---|
| Age, y | 35.53 (2.09) | 35.95 (2) | 0.098 | |||||
| BMI (kg/m2) | 23.32 (3.83) | 23.33 (4.49) | 0.995 | |||||
| Basal FSH (mIU/mL) | 8.08 (2.82) | 8.75 (3.92) | 0.098 | |||||
| †AFC (n) | 13.6 (6.02) | 12.11 (6.25) | 0.021 | |||||
| Ovarian stimulation duration (days) | 11.29 (1.61) | 11.08 (1.53) | 0.376 | |||||
| †GT total dose (mIU/mL) | 3170.05 (919.54) | 3317.16 (835.58) | 0.375 | |||||
| †Peak E2 (pg/mL) | 2506.93 (1644.33) | 3631.45 (2601.31) | <0.001 | |||||
| †Peak P (ng/mL) | 1.30 (0.75) | 1.04 (0.53) | 0.013 | |||||
| †Oocytes retrieved (n) | 16.81 (11.23) | 14.13 (10.38) | 0.055 | |||||
| †MII oocytes (n) | 13.20 (9.32) | 10.33 (7.65) | 0.019 | |||||
| Maturity rate (%) | 78.03 (17.14) | 74.24 (22.09) | 0.057 | |||||
*After ANCOVA with antral follicle count (AFC) as a covariate.
Values are presented as mean (standard deviation) or number (%). A p value of < 0.05 was considered significant.
†The p value was calculated after log transformation for normal distribution.
rFSH, recombinant follicle-stimulating hormone; hp-hMG, highly purified-human menopausal gonadotropin; GnRH, gonadotropin-releasing hormone; BMI, body mass index; FSH, follicle-stimulating hormone; AFC, antral follicle count; GT, gonadotropins; E2, estradiol; P, progesterone; MII, metaphase II
Note: Standard reference ranges: FSH: 1-9.2 mIU/mL